Fig. 2From: A real-world study of acute and preventive medication use, adherence, and persistence in patients prescribed fremanezumab in the United StatesAdherence to fremanezumab therapy. PDC proportion of days covered; MPR medication possession ratio. P values calculated between quarterly dosing group and monthly dosing group via independent t-test. aP = 0.005. bP = 0.045Back to article page